KEI submissions to the WHO Model List of Essential Medicines (EML) 14 January 2013, Knowledge Ecology International (KEI), the University of California (San Francisco), Universities Allied for Essential Medicines (UAEM), Third World Network (TWN) and Young Professionals Chronic Disease Network:… Continue Reading →
On Wednesday 20th January 2020, at the 148th session of the World Health Organisation (WHO) Executive Board, the issue of financing and implementation of programme budget 2020-2021, the draft proposed for programme budget 2022-2023 and the issue of sustainable financing… Continue Reading →
KEI-T-DM1-Kadcyla-EML-20Dec2016
KEI research associate Paul Miano has written the following paper: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines. KEI Research Note 2011:1,
A full copy of the paper is available in PDF format here.
The following is from the introduction (sans footnotes, which are in the PDF version):
Introduction and Summary
Continue Reading →
https://www.keionline.org/misc-docs/b_b_igwg/working_document_barbados_bolivia.pdf April 2008 According to resolution WHA60.30 on Public Health, Innovation and Intellectual Property, the Director-General of the WHO is asked: (4) to encourage the development of proposals for health-needs driven research and development for discussion at the Intergovernmental Working… Continue Reading →
March 2, 2007 Secretary of the Expert Committee on the Selection and Use of Essential Medicines (2007)Department of Medicines Policy and Standards (PSM)Health Technology & PharmaceuticalsWorld Health OrganizationCH-1211 Geneva 27Switzerland Via e-mail: emisecretariat@who.int RE: Request for changes in the WHO Model… Continue Reading →